bcl-2 Protein in Non-Small-Cell Lung Carcinoma

New England Journal of Medicine

Volumn 329, Issue 10, 1993, Pages 690-694

  Pezzella, Francesco ^a   Turley, Helen ^a   Kuzu, Isinzu ^a   Tungekar, Mohammed Fahim ^a   Dunnill, Michael S ^a   Pierce, Chris B ^a   Harris, Adrian ^a   Gatter, Kevin C ^a   Mason, David Y ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE BCL 2; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; REGRESSION ANALYSIS; SUPPORT, NON-U.S. GOV'T; TUMOR MARKERS, BIOLOGICAL;

EID: 0027186201     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199309023291003     Document Type: Article

References (28)

1. Tsujimoto Y, Croce CM Analysis of the structure, transcripts and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci U S A 1986; 83: 5214-5218
2. Pezzella F, Ralfkiaer E, Gatter KC, Mason DY The 14;18 translocation in European cases of follicular lymphoma: comparison of Southern blotting and the polymerase chain reaction. Br J Haematol 1990; 76: 58-64
3. Aisenberg AC, Wilkes BM, Jacobson JO The bcl-2 gene is rearranged in many diffuse B-cell lymphomas. Blood 1988; 71: 969-972
4. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984; 226: 1097-1099
5. Tsujimoto Y, Ikegaki N, Croce CM Characterization of the protein product of bcl-2, the gene involved in human follicular lymphoma. Oncogene 1987; 2: 3-7
6. Cleary ML, Smith SD, Sklar J Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 1986; 47: 19-28
7. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-336
8. McDonnell TJ, Deane N, Platt FM, bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989; 57: 79-88
9. Vaux DL, Cory S, Adams JM Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-442
10. Korsmeyer SJ Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992; 80: 879-886
11. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci U S A 1991; 88: 6961-6965
12. McVie JG. Cancer of the lung and pleura. In: Hossfeld DK, Sherman CD, Love RR, Bosch FX, eds. Manual of clinical oncology. 5th ed. Berlin, Germany: Springer-Verlag, 1990:217-27.
13. Carr DT, Mountain CF. Staging lung cancer. In: Strauss MJ, ed. Lung cancer: clinical diagnosis and treatment. New York: Grune & Stratton, 1983:201-12.
14. Mountain CF A new international staging system for lung cancer. Chest 1986; 89: Suppl: 225S-233S
15. Cordell JL, Falini B, Erber WN, Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984; 32: 219-229
16. Pezzella F, Tse AG, Cordell JL, Pulford KA, Gatter KC, Mason DY Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol 1990; 137: 225-232
17. Lee JS, Ro JY, Sahin AA, Expression of blood-group antigen A -- a favorable prognostic factor in non-small-cell lung cancer. N Engl J Med 1991; 324: 1084-1090
18. b antigens with survival in patients with carcinoma of the lung. N Engl J Med 1992; 327: 14-18
19. Kaplan EL, Meier P Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481
20. Peto R, Pike MC, Armitage P, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977; 35: 1-39
21. Machin D, Gardner MJ. Calculating confidence intervals for survival time analyses. In: Gardner MJ, Altman DG, eds. Statistics with confidence: confidence intervals and statistical guidelines. London: British Medical Journal, 1989:64-70.
22. Altman DG. Comparing groups: categorical data. In: Altman DG. Practical statistics for medical research. London: Chapman & Hall, 1991:229-76.
23. Comparison of several groups. In: Armitage P, Berry G. Statistical methods in medical research. 2nd ed. Oxford, England: Blackwell, 1987:186-213.
24. Pezzella F, Gatter KC, Mason DY, Bcl-2 protein expression in follicular lymphomas in absence of 14;18 translocation. Lancet 1990; 336: 1510-1511
25. Reed JC, Tsujimoto Y, Alpers JD, Croce CM, Nowell PC Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation. Science 1987; 236: 1295-1299
26. Lee JS, Hong WK Prognostic factors in lung cancer. N Engl J Med 1992; 327: 47-48
27. Slebos RJC, Kibbelaar RE, Dalesio O, K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990; 323: 561-565
28. Bailar JC III, Mosteller F, eds. Medical uses of statistics. 2nd ed. Boston: NEJM Books, 1992.